| A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer M Nakano, T Fukami, S Gotoh, M Nakajima Journal of Biological Chemistry 292 (12), 4873-4884, 2017 | 102 | 2017 |
| Current knowledge of microRNA-mediated regulation of drug metabolism in humans M Nakano, M Nakajima Expert opinion on drug metabolism & toxicology 14 (5), 493-504, 2018 | 55 | 2018 |
| RNA editing modulates human hepatic aryl hydrocarbon receptor expression by creating microRNA recognition sequence M Nakano, T Fukami, S Gotoh, M Takamiya, Y Aoki, M Nakajima Journal of Biological Chemistry 291 (2), 894-903, 2016 | 55 | 2016 |
| CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126 M Nakano, Y Fukushima, S Yokota, T Fukami, M Takamiya, Y Aoki, ... Drug Metabolism and Disposition 43 (5), 703-712, 2015 | 51 | 2015 |
| Single-nucleotide polymorphisms in cytochrome P450 2E1 (CYP2E1) 3′-untranslated region affect the regulation of CYP2E1 by miR-570 M Nakano, T Mohri, T Fukami, M Takamiya, Y Aoki, HL McLeod, ... Drug Metabolism and Disposition 43 (10), 1450-1457, 2015 | 39 | 2015 |
| Methylation of adenosine at the N6 position post-transcriptionally regulates hepatic P450s expression M Nakano, K Ondo, S Takemoto, T Fukami, M Nakajima Biochemical Pharmacology 171, 113697, 2020 | 28 | 2020 |
| Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics M Nakano, M Nakajima Pharmacology & Therapeutics 181, 13-21, 2018 | 27 | 2018 |
| m6A modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2 S Takemoto, M Nakano, T Fukami, M Nakajima Biochemical Pharmacology 193, 114766, 2021 | 25 | 2021 |
| miR-141-3p commonly regulates human UGT1A isoforms via different mechanisms N Tatsumi, S Tokumitsu, M Nakano, T Fukami, M Nakajima Drug Metabolism and Pharmacokinetics 33 (4), 203-210, 2018 | 20 | 2018 |
| The N6-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression K Ondo, M Isono, M Nakano, S Hashiba, T Fukami, M Nakajima Biochemical Pharmacology 189, 114402, 2021 | 15 | 2021 |
| Strain and sex differences in drug hydrolase activities in rodent livers F Kisui, T Fukami, M Nakano, M Nakajima European Journal of Pharmaceutical Sciences 142, 105143, 2020 | 15 | 2020 |
| Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans Y Sakai, T Fukami, M Nagaoka, K Hirosawa, H Ichida, R Sato, K Suzuki, ... Life Sciences 284, 119896, 2021 | 13 | 2021 |
| RNA editing enzymes modulate the expression of hepatic CYP2B6, CYP2C8, and other cytochrome P450 isoforms K Nozaki, M Nakano, C Iwakami, T Fukami, M Nakajima Drug Metabolism and Disposition 47 (6), 639-647, 2019 | 13 | 2019 |
| SLC35B1 significantly contributes to the uptake of UDPGA into the endoplasmic reticulum for glucuronidation catalyzed by UDP-glucuronosyltransferases K Ondo, H Arakawa, M Nakano, T Fukami, M Nakajima Biochemical Pharmacology 175, 113916, 2020 | 12 | 2020 |
| Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24 W Liu, M Nakano, T Nakanishi, M Nakajima, I Tamai Drug Metabolism and Pharmacokinetics 35 (6), 515-521, 2020 | 11 | 2020 |
| Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers K Amai, T Fukami, H Ichida, A Watanabe, M Nakano, K Watanabe, ... Drug Metabolism and Pharmacokinetics 35 (6), 539-547, 2020 | 11 | 2020 |
| Role of human arylacetamide deacetylase (AADAC) on hydrolysis of eslicarbazepine acetate and effects of AADAC genetic polymorphisms on hydrolase activity K Hirosawa, T Fukami, K Tashiro, Y Sakai, F Kisui, M Nakano, ... Drug Metabolism and Disposition 49 (4), 322-329, 2021 | 10 | 2021 |
| Hydrolase activities of cynomolgus monkey liver microsomes and recombinant CES1, CES2, and AADAC S Honda, T Fukami, T Tsujiguchi, Y Zhang, M Nakano, M Nakajima European Journal of Pharmaceutical Sciences 161, 105807, 2021 | 8 | 2021 |
| Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin M Asakura, M Nakano, K Hayashida, H Fujii, M Nakajima, K Atsuda, T Itoh, ... Drug Metabolism and Pharmacokinetics 29 (6), 463-469, 2014 | 8 | 2014 |
| Quantitative evaluation of the contribution of each aldo-keto reductase and short-chain dehydrogenase/reductase isoform to reduction reactions of compounds containing a ketone … H Ichida, T Fukami, K Amai, K Suzuki, K Mishiro, S Takano, W Obuchi, ... Drug Metabolism and Disposition 51 (1), 17-28, 2023 | 6 | 2023 |
